-
1Academic Journal
Συγγραφείς: Grachev, V. G., Vedenskaya, S. S., Smolenskaya, O. G., Грачев, В. Г., Веденская, С. С., Смоленская, О. Г
Θεματικοί όροι: CARDIOVASCULAR DISEASE, POLYVASCULAR DISEASE, SCREENING, RISK ASSESSMENT, SECONDARY PREVENTION, ANTITHROMBOTIC THERAPY, СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ, МУЛЬТИФОКАЛЬНОЕ АРТЕРИАЛЬНОЕ ПОРАЖЕНИЕ, СКРИНИНГ, СТРАТИФИКАЦИЯ РИСКА, ВТОРИЧНАЯ ПРОФИЛАКТИКА, АНТИТРОМБОТИЧЕСКИАЯ ТЕРАПИЯ
Περιγραφή αρχείου: application/pdf
Relation: Scopus; Грачев В. Г., Веденская С. С., Смоленская О. Г. Особенности вторичной профилактики у пациентов с мультифокальным артериальным поражением. Часть 1: стратификация риска и диагностика. Рациональная Фармакотерапия в Кардиологии 2021;17(1):83; http://elib.usma.ru/handle/usma/6969
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/6969
-
2Academic Journal
Συγγραφείς: Grachev, V. G., Vedenskaya, S. S., Smolenskaya, O. G., Грачев, В. Г., Веденская, С. С., Смоленская, О. Г.
Θεματικοί όροι: CARDIOVASCULAR DISEASE, POLYVASCULAR DISEASE, SCREENING, RISK ASSESSMENT, SECONDARY PREVENTION, ANTITHROMBOTIC THERAPY, СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ, МУЛЬТИФОКАЛЬНОЕ АРТЕРИАЛЬНОЕ ПОРАЖЕНИЕ, СКРИНИНГ, СТРАТИФИКАЦИЯ РИСКА, ВТОРИЧНАЯ ПРОФИЛАКТИКА, АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ
Περιγραφή αρχείου: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7316
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7316
-
3Academic Journal
Συγγραφείς: V. Grachev G., S. Vedenskaya S., O. Smolenskaya G., В. Грачев Г., С. Веденская С., О. Смоленская Г.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 1 (2021); 83-91 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 1 (2021); 83-91 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: cardiovascular disease, polyvascular disease, screening, risk assessment, secondary prevention, antithrombotic therapy, сердечно-сосудистые заболевания, мультифокальное артериальное поражение, скрининг, стратификация риска, вторичная профилактика, антитромботическиая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2391/2117; Bonaca M.P. Polyvascular disease and risk: When two is not better than one. Vasc Med. 2018;23(6):531-533. DOI:10.1177/1358863X18796936.; Desormais I., Vlachopoulos C., Aboyans V. Panvascular disease - epidemiology and prevention. Cor et Vasa. 2018;60(1):e3-e8. DOI:10.1016/j.crvasa.2017.12.004.; Aboyans V., Ricco J.B., Bartelink M.E.L., et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. DOI:10.1093/eurheartj/ehx095.; Акберов Р.Ф., Шарафеев А.З., Михайлов М.К., и др. Прогрессирующий мультифокальный атеросклероз: этиология, клинико-лучевая диагностика, современные аспекты лечения. Казань: Идел-Пресс; 2008.; Барбараш О.Л., Кашталап В.В. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные Проблемы Сердечно-сосудистых Заболеваний. 2012;(1):12-6. DOI:10.17802/2306-1278-2012-1-12-16.; Bhatt D.L., Steg P.G., Ohman E.M., et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. DOI:10.1001/jama.295.2.180.; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE SteeringCommittee. Lancet. 1996;348(9038):1329-39. DOI:10.1016/s0140-6736(96)09457-3.; Bhatt D.L., Peterson E.D., Harrington R.A., et al. CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009;30(10):1195-202. DOI:10.1093/eurheartj/ehp099.; Subherwal S., Bhatt D.L., Li S., et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5(4):541-9. DOI:10.1161/CIRCOUTCOMES.111.964379.; Vagnarelli F., Corsini A., Lorenzini M., et al. Long-term prognostic role of cerebrovascular disease and peripheral arterial disease across the spectrum of acute coronary syndromes. Atherosclerosis. 2016;245:43-9. DOI:10.1016/j.atherosclerosis.2015.11.014.; Heldner M.R, Li L., Lovett N.G., et al. Oxford Vascular Study. Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. Stroke. 2018;49(7):1639-1646. DOI:10.1161/STROKEAHA.118.020913.; Gutierrez J.A., Mulder H., Jones WS., et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018;1(7):e185239. DOI:10.1001/jamanetworkopen.2018.5239.; van Kuijk J.P., Flu W.J., Welten G.M., et al. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur Heart J. 2010;31(8):992-9. DOI:10.1093/eurheartj/ehp553.; Steg P.G., Bhatt D.L., Wilson P.W., et al. REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197-206. DOI:10.1001/jama.297.11.1197.; Alberts M.J., Bhatt D.L., Mas J.L., et al. REduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30:2318-26. DOI:10.1093/eurheartj/ehp355.; Bhatt D.L., Eagle K.A., Ohman E.M., et al. REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-7. DOI:10.1001/jama.2010.1322.; Hirsh J., Bhatt D.L. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004;164(19):2106-10. DOI:10.1001/archinte.164.19.2106.; Mukherjee D., Eagle KA., Kline-Rogers E., et al. GRACE Investigators. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100(1):1-6. DOI:10.1016/j.amjcard.2007.02.046.; Ferreira-González I., Permanyer Miralda G., Heras M., et al. Investigadores del Estudio MASCARA. Prognosis and management of patients with acute coronary syndrome and polyvascular disease. Rev Esp Cardiol. 2009;62(9):1012-21. DOI:10.1016/s1885-5857(09)73267-0.; Attar R., Wester A., Koul S., et al. Peripheral artery disease and outcomes in patients with acute myocardial infarction. Open Heart. 2019;6(1):e001004. DOI:10.1136/openhrt-2018-001004.; Collet J.P., Cayla G., Ennezat P.V., et al. AMERICA Investigators. Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. Int J Cardiol. 2018;254:36-42. DOI:10.1016/j.ijcard.2017.11.081.; Knuuti J., Wijns W., Saraste A., et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77. DOI:org/10.1093/eurheartj/ehz425.; Gallino A., Aboyans V., Diehm C., et al. European Society of Cardiology Working Group on Peripheral Circulation. Non-coronary atherosclerosis. Eur Heart J. 2014;35(17):1112-9. DOI:10.1093/eurheartj/ehu071.; Hertzer N.R., Beven E.G., Young J., et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. AnnSurg. 1984;199(2):223-33. DOI:10.1097/00000658-198402000-00016.; Duran N.E., Duran I., Gürel E. et al. Coronary artery disease in patients with peripheral artery disease. Heart Lung. 2010;39(2):116-20. DOI:10.1016/j.hrtlng.2009.07.004.; Hur D.J., Kizilgul M., Aung W.W., et al. Frequency of coronary artery disease in patients undergoing peripheral artery disease surgery. Am J Cardiol. 2012;110(5):736-40. DOI:10.1016/j.amjcard.2012.04.059.; Gutierrez J.A., Bhatt D.L., Banerjee S., et al. Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. Am Heart J. 2019;213:47-56. DOI:10.1016/j.ahj.2019.04.004.; Her K., Choi C., Park Y. Concomitant peripheral artery disease and asymptomatic coronary artery disease: a management strategy. Ann Vasc Surg. 2008;22(5):649-56. DOI:10.1016/j.avsg.2008.01.010.; Khandelwal A., Kondo T., Amanuma M., et al. Single injection protocol for coronary and lower extremity CT angiographies in patients suspected for peripheral arterial disease. Medicine (Baltimore). 2016;95(46):e5410. DOI:10.1097/MD.0000000000005410.; Krievins D., Zellans E., Erglis A., et al. High prevalence of asymptomatic ischemia-producing coronary stenosis in patients with critical limb ischemia: anatomic and functional assessment with coronary CT-derived fractional flow reserve (FFRCT). Vasc Dis Manag. 2018;15(9):E96-E101.; Touzé E., Varenne O., Chatellier G., et al. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke. 2005;36(12):2748-55. DOI:10.1161/01.STR.0000190118.02275.33.; Mohan K.M., Wolfe C.D., Rudd A.G., et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489-94. DOI:10.1161/STROKEAHA.110.602615.; Boulanger M., Béjot Y., Rothwell P.M., et al. Long-Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and MetaAnalysis. J Am Heart Assoc. 2018;7(2):e007267. DOI:10.1161/JAHA.117.007267.; Kelly P.J., Crispino G., Sheehan O., et al. Incidence, event rates, and early outcome of stroke in Dublin, Ireland: the North Dublin population stroke study. Stroke. 2012;43(8):2042-7. DOI:10.1161/STROKEAHA.111.645721.; Rothwell P.M., Coull A.J., Giles M.F., et al. Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363(9425):1925-33. DOI:10.1016/S0140-6736(04)16405-2.; Venketasubramanian N., Röther J., Bhatt D.L., et al. REACH Investigators. Two-year vascular event rates in patients with symptomatic cerebrovascular disease: the REACH registry. Cerebrovasc Dis. 2011;32(3):254-60. DOI:10.1159/000328650.; Adams R.J., Chimowitz M.I., Alpert J.S., et al. American Heart Association/American Stroke Association. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke. 2003;34(9):2310-22. DOI:10.1161/01.STR.0000090125.28466.E2.; Amarenco P., Lavallée P.C., Labreuche J., et al. Prevalence of coronary atherosclerosis in patients with cerebral infarction. Stroke. 2011;42(1):22-9. DOI:10.1161/STROKEAHA.110.584086.; Hoshino A., Nakamura T., Enomoto S., et al. Clinical utility of evaluating intracranial artery stenosis and silent brain infarction to predict the presence of subclinical coronary artery disease in ischemic stroke patients. Intern Med. 2008;47(20):1775-81. DOI:10.2169/internalmedicine.47.1314.; Seo W.K., Yong H.S., Koh S.B., et al. Correlation of coronary artery atherosclerosis with atherosclerosis of the intracranial cerebral artery and the extracranial carotid artery. Eur Neurol. 2008;59(6):292- 8. DOI:10.1159/000121418.; Calvet D., Touzé E., Varenne O., et al. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. Circulation. 2010;121(14):1623-9. DOI:10.1161/CIRCULATIONAHA.109.906958.; Cho H.J., Lee J.H., Kim Y.J., et al. Comprehensive evaluation of coronary artery disease and aortic atherosclerosis in acute ischemic stroke patients: usefulness based on Framingham risk score and stroke subtype. Cerebrovasc Dis. 2011;31(6):592-600. DOI:10.1159/000326075.; Yoon Y.E., Chang H.J., Cho I., et al. Incidence of subclinical coronary atherosclerosis in patients with suspected embolic stroke using cardiac computed tomography. Int J Cardiovasc Imaging. 2011;27(7):1035-44. DOI:10.1007/s10554-010-9743-8.; Kim S.J., Choe Y.H., Park S.J., et al. Routine cardiac evaluation in patients with ischaemic stroke and absence of known atrial fibrillation or coronary heart disease: transthoracic echocardiography vs. multidetector cardiac computed tomography. Eur J Neurol. 2012;19(2):317-23. DOI:10.1111/j.1468-1331.2011.03505.x.; Ahn S.S., Nam H.S., Heo J.H., et al. Ischemic stroke: measurement of intracranial artery calcifications can improve prediction of asymptomatic coronary artery disease. Radiology. 2013;268(3):842-9. DOI:10.1148/radiol.13122417.; Cha M.J., Lee H.S., Kim Y.D., et al. The association between asymptomatic coronary artery disease and CHADS2 and CHA2DS2-VASc scores in patients with stroke. Eur J Neurol. 2013;20(9):1256- 63. DOI:10.1111/ene.12158.; Chimowitz M.I., Poole R.M., Starling MR., et al. Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. Stroke. 1997;28(5):941-5. DOI:10.1161/01.str.28.5.941.; Okin P.M., Roman M.J., Schwartz J.E., et al. Relation of exercise-induced myocardial ischemia to cardiac and carotid structure. Hypertension. 1997;30(6):1382-8. DOI:10.1161/01.hyp.30.6.1382.; Hofmann R., Kypta A., Steinwender C., et al. Coronary angiography in patients undergoing carotid artery stenting shows a high incidence of significant coronary artery disease. Heart. 2005;91(11):1438-41. DOI:10.1136/hrt.2004.050906.; Chimowitz M.I., Weiss D.G., Cohen S.L., et al. Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167. Stroke. 1994;25(4):759-65. DOI:10.1161/01.str.25.4.759.; Giannopoulos A., Kakkos S., Abbott A., et al. Long-term Mortality in Patients with Asymptomatic Carotid Stenosis: Implications for Statin Therapy. Eur J VascEndovasc Surg. 2015;50(5):573-82. DOI:10.1016/j.ejvs.2015.06.115.; Illuminati G., Ricco J.B., Greco C., et al. Systematic preoperative coronary angiography and stenting improves postoperative results of carotid endarterectomy in patients with asymptomatic coronary artery disease: a randomised controlled trial. Eur J Vasc Endovasc Surg. 2010;39(2):139-45. DOI:10.1016/j.ejvs.2009.11.015.; Illuminati G., Schneider F., Greco C., et al. Long-term results of a randomized controlled trial analyzing the role of systematic pre-operative coronary angiography before elective carotid endarterectomy in patients with asymptomatic coronary artery disease. Eur J VascEndovasc Surg. 2015;49(4):366-74. DOI:10.1016/j.ejvs.2014.12.030.; Aboyans V., Lacroix P. Indications for carotid screening in patients with coronary artery disease. Presse Med. 2009;38(6):977-86. DOI:10.1016/j.lpm.2009.02.015.; Lin J.C., Kabbani L.S., Peterson E.L., et al. Clinical utility of carotid duplex ultrasound prior to cardiac surgery. J Vasc Surg. 2016;63(3):710-4. DOI:10.1016/j.jvs.2015.10.008.; Steinvil A., Sadeh B., Arbel Y., et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll Cardiol. 2011;57(7):779-83. DOI:10.1016/j.jacc.2010.09.047.; Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-24. DOI:10.1001/jama.286.11.1317.; Diehm C., Schuster A., Allenberg J.R., et al. High prevalence of peripheral arterial disease and comorbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172(1):95- 105. DOI:10.1016/s0021-9150(03)00204-1.; АССХР/РОАСХ/ РОХ/РКО/РАЭ. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей (2019) [цитировано 20.01.2021]. Доступно на: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf.; Fowkes F.G., Murray G.D., et al., Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208. DOI:10.1001/jama.300.2.197.; Hajibandeh S., Hajibandeh S., Shah S., et al. Prognostic significance of ankle brachial pressure index: A systematic review and meta-analysis. Vascular. 2017;25(2):208-24. DOI:10.1177/1708538116658392.; Banerjee A., Fowkes F.G., Rothwell P.M. Associations between peripheral artery disease and ischemic stroke: implications for primary and secondary prevention. Stroke. 2010;41(9):2102-7. DOI:10.1161/STROKEAHA.110.582627.; Agnelli G., Cimminiello C., Meneghetti G., et al. Polyvascular Atherothrombosis Observational Survey (PATHOS) Investigators. Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost. 2006;4(12):2599-606. DOI:10.1111/j.1538-7836.2006.02225.x.; Serena J., Segura T., Roquer J., et al. ARTICO Study. The ARTICO study: identification of patients at high risk of vascular recurrence after a first non-cardioembolic stroke. BMC Neurol. 2015;15:28. DOI:10.1186/s12883-015-0278-4.; Hong J.B., Leonards C.O., Endres M., et al. Ankle-Brachial Index and Recurrent Stroke Risk: MetaAnalysis. Stroke. 2016;47(2):317-22. DOI:10.1161/STROKEAHA.115.011321.; Meizels A., Zeitoun D.M., Bataille V., et al. ALLIANCE investigators on behalf of the working group on Epidemiology of the French Society of Cardiology. Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction. The Alliance project. Arch Cardiovasc Dis. 2010;103(4):207-14. DOI:10.1016/j.acvd.2010.02.002.; Bonaca M.P., Bhatt D.L., Storey R.F., et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719-28. DOI:10.1016/j.jacc.2016.03.524.; Bonaca M.P., Gutierrez J.A., Cannon C., et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934-43. DOI:10.1016/S2213-8587(18)30290-0.; Jönelid B., Johnston N., Berglund L., et al. Ankle brachial index most important to identify polyvascular disease in patients with non-ST elevation or ST-elevation myocardial infarction. Eur J Intern Med. 2016;30:55-60. DOI:10.1016/j.ejim.2015.12.016.; Kownator S., Cambou J.P., Cacoub P., et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis. 2009;102(8-9):625-31. DOI:10.1016/j.acvd.2009.05.004.; Lee J.Y., Lee S.W., Lee W.S., et al. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease. JACC Cardiovasc Interv. 2013;6(12):1303-13. DOI:10.1016/j.jcin.2013.08.008.; Saleh A., Makhamreh H., Qoussoos T., et al. Prevalence of previously unrecognized peripheral arterial disease in patients undergoing coronary angiography. Medicine (Baltimore). 2018;97(29):e11519. DOI:10.1097/MD.0000000000011519.; Barbarash O.L., Zykov M.V., Pecherina T.B., et al. The prognostic value of peripheral artery diseases in patients with ST-segment elevation myocardial infarction. Dis Markers. 2013;35(6):877-82. DOI:10.1155/2013/487807.; Falcão F.J., Rodrigues Alves C.M., Caixeta A., et al. Relation between the ankle-brachial index and the complexity of coronary artery disease in older patients. Clin Interv Aging. 2013;8:1611-6. DOI:10.2147/CIA.S52778.; Sabedotti M., Sarmento-Leite R., Quadros A. Ankle-Brachial Index as a Predictor of Significant Coronary Artery Disease in Patients Undergoing Coronary Angiography. Rev Bras Cardiol Invasiva. 2014;22(4):359-63. DOI:10.1590/0104-1843000000060.; Sadeghi M., Heidari R., Mostanfar B., et al. The Relation Between Ankle-Brachial Index (ABI) and Coronary Artery Disease Severity and Risk Factors: An Angiographic Study. ARYA Atheroscler. 2011;7(2):68-73. PMID: 22577449.; Korkmaz L., Adar A., Erkan H., et al. Ankle-brachial index and coronary artery lesion complexity in patients with acute coronary syndromes. Angiology. 2012;63(7):495-9. DOI:10.1177/0003319711429561.; Amer M.S., Tawfik H.M., Elmoteleb A.M., et al. Correlation between ankle brachial index and coronary artery disease severity in elderly Egyptians. Angiology. 2014;65(10):891-5. DOI:10.1177/0003319713510594.; Bryniarski K.L., Tokarek T., Bryk T., et al. Intima-media thickness and ankle-brachial index are correlated with the extent of coronary artery disease measured by the SYNTAX score. Postepy Kardiol Interwencyjnej. 2018;14(1):52-8. DOI:10.5114/aic.2018.74355.; Sebastianski M., Narasimhan S., Graham MM., et al. Usefulness of the ankle-brachial index to predict high coronary SYNTAX scores, myocardium at risk, and incomplete coronary revascularization. Am J Cardiol. 2014;114(11):1745-9. DOI:10.1016/j.amjcard.2014.09.010.; https://www.rpcardio.com/jour/article/view/2391
-
4Academic Journal
Συγγραφείς: V. Grachev G., S. Vedenskaya S., O. Smolenskaya G., В. Грачев Г., С. Веденская С., О. Смоленская Г.
Συνεισφορές: The publication of the article is supported by Bayer, but it did not affect his own opinion of the authors, Публикация статьи поддержана компанией Байер, что никоим образом не повлияло на собственное мнение авторов
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 239-248 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 239-248 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: cardiovascular disease, polyvascular disease, screening, risk assessment, secondary prevention, antithrombotic therapy, сердечно-сосудистые заболевания, мультифокальное артериальное поражение, скрининг, стратификация риска, вторичная профилактика, антитромботическая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2376/2145; Aboyans V, Ricco JB, Bartelink MEL, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. DOI:10.1093/eurheartj/ehx095.; Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.; Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eu-rheartj/ehy339.; Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (In Russ.) [Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2020;25(3):3786]. DOI:10.15829/1560-4071-2020-3-3786.; SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. DOI:10.1056/NEJMoa1511939.; Fudim M, Jones WS. New Curveball for Hypertension Guidelines? Circulation. 2018;138(17):1815- 8. DOI:10.1161/CIRCULATIONAHA.118.036409.; Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55(1):48-53. DOI:10.1161/HYPERTENSIONAHA.109.142240.; Itoga NK, Tawfik DS, Lee CK, et al. Association of Blood Pressure Measurements With Peripheral Artery Disease Events. Circulation. 2018;138(17):1805-14. DOI:10.1161/CIRCULATIONAHA.118.033348.; Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107(5):753- 6. DOI:10.1161/01.cir.0000049640.46039.52.; Ostergren J, Sleight P, Dagenais G, et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17-24. DOI:10.1016/j.ehj.2003.10.033.; ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. DOI:10.1056/NEJMoa0801317.; Armstrong EJ, Chen DC, Singh GD, et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med. 2015;20(3):237-44. DOI:10.1177/1358863X15574321.; Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013(9):CD005508. DOI:10.1002/14651858.CD005508.pub3.; Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87(11):1284-6. DOI:10.1016/s0002-9149(01)01521-1.; Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6(12):934- 43. DOI:10.1016/S2213-8587(18)30290-0.; Jukema JW, Szarek M, Zijlstra LE, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74(9):1167-76. DOI:10.1016/j.jacc.2019.03.013.; Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. DOI:10.1161/CIRCULATIONAHA.117.032235.; Verma S, Bhatt DL, Bain SC, et al. LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018;137(20):2179-83. DOI:10.1161/CIRCULATIONAHA.118.033898.; Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57. DOI:10.1056/NEJMoa1611925.; Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137(4):405-7. DOI:10.1161/CIRCULATIONAHA.117.032031.; Bonaca MP, Wiviott SD, Zelniker TA, et al. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734- 47. DOI:10.1161/CIRCULATIONAHA.119.044775.; McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303.; Li D, Yang JY, Wang T, et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. Diabetes Metab. 2018 Nov;44(5):410-4. DOI:10.1016/j.diabet.2018.02.001.; Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab. 2018;20(6):1531-4. DOI:10.1111/dom.13255.; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329- 39. DOI:10.1016/s0140-6736(96)09457-3.; Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. DOI:10.1093/eurheartj/ehx419.; Hiatt WR, Fowkes FG, Heizer G, Berger JS, et al. EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017;376(1):32- 40. DOI:10.1056/NEJMoa1611688.; Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17. DOI:10.1056/NEJMoa060989.; Bhatt DL, Flather MD, Hacke W, et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982-8. DOI:10.1016/j.jacc.2007.03.025.; Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-66. DOI:10.1056/NEJMoa1409312.; Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.; Secemsky EA, Yeh RW, Kereiakes DJ, et al. Dual Antiplatelet Therapy Study Investigators. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017;10(9):942- 954. DOI:10.1016/j.jcin.2017.02.013.; Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016;67(23):2719-28. DOI:10.1016/j.jacc.2016.03.524.; Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS- TIMI 54. Eur Heart J. 2016;37(14):1133-42. DOI:10.1093/eurheartj/ehv531.; Fender AC, Rauch BH, Geisler T, Schror K. Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation? Thromb Haemost. 2017;117(11):2013-25. DOI:10.1160/TH17-03-0219.; Borissoff JI, Joosen IA, Versteylen MO, et al. Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. JACC Cardiovasc Imaging. 2012;5(12):1201-10. DOI:10.1016/j.jcmg.2012.01.023.; Gurbel PA, Bliden KP, Navickas I, et al. Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking? J Thromb Haemost. 2007;5(11):2300-1. DOI:10.1111/j.1538-7836.2007.02749.x.; Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282(21):2058-67. DOI:10.1001/jama.282.21.2058.; Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S-69S. DOI:10.1016/s0735-1097(02)02776-6.; Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519-26. DOI:10.1093/eurheartj/ehi485.; Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708. DOI:10.1056/NE-JMoa1105819.; Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. DOI:10.1056/NEJMoa1112277.; Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. DOI:10.1056/NE-JMoa1709118.; Connolly SJ, Eikelboom JW, Bosch J, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. DOI:10.1016/S0140-6736(17)32458-3.; Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. DOI:10.1016/S0140-6736(17)32409-1.; Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139(9):1134-1145. DOI:10.1161/CIRCULATIONAHA.118.035864.; Российское кардиологическое общество (Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. DOI:10.15829/1560-4071-2020-4076.; Maron DJ, Hochman JS, Reynolds HR, et al. ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-407. DOI:10.1056/NE-JMoa1915922.; https://www.rpcardio.com/jour/article/view/2376